Summit Therapeutics (SMMT) Return on Assets: 2017-2024
Historic Return on Assets for Summit Therapeutics (SMMT) over the last 2 years, with Dec 2024 value amounting to -0.39%.
- Summit Therapeutics' Return on Assets rose 6.00% to -0.39% in Q4 2024 from the same period last year, while for Dec 2024 it was -0.39%, marking a year-over-year increase of 6.00%. This contributed to the annual value of -0.74% for FY2024, which is 68.00% up from last year.
- According to the latest figures from Q4 2024, Summit Therapeutics' Return on Assets is -0.39%, which was down 19.61% from -0.33% recorded in Q3 2024.
- Summit Therapeutics' 5-year Return on Assets high stood at -0.09% for Q4 2022, and its period low was -0.45% during Q4 2023.
- In the last 3 years, Summit Therapeutics' Return on Assets had a median value of -0.31% in 2024 and averaged -0.29%.
- In the last 5 years, Summit Therapeutics' Return on Assets plummeted by 36bps in 2023 and then increased by 6bps in 2024.
- Quarterly analysis of 4 years shows Summit Therapeutics' Return on Assets stood at -0.21% in 2020, then reached -0.09% in 2022, then crashed by 36bps to -0.45% in 2023, then climbed by 6bps to -0.39% in 2024.
- Its Return on Assets stands at -0.39% for Q4 2024, versus -0.33% for Q3 2024 and -0.45% for Q4 2023.